{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:27:17Z","timestamp":1792736837690,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.canlet.2022.215661","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T03:07:11Z","timestamp":1647832031000},"page":"215661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models"],"prefix":"10.1016","volume":"535","author":[{"given":"Wenmo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xupu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2022.215661_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2022.215661_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: a current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J. Virol."},{"key":"10.1016\/j.canlet.2022.215661_bib3","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2022.215661_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.canlet.2022.215661_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.canlet.2022.215661_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J .Immunother. Cancer"},{"key":"10.1016\/j.canlet.2022.215661_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/mt.2012.211","article-title":"Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic Herpes simplex virus","volume":"21","author":"Uchida","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215661_bib8","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.3390\/ijms21218310","article-title":"Herpes simplex virus oncolytic immunovirotherapy: the blossoming branch of multimodal therapy","volume":"21","author":"Menotti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2022.215661_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.177","article-title":"Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity","volume":"7","author":"Yan","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2022.215661_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.critrevonc.2019.08.008","article-title":"The TRAIL to cancer therapy: hindrances and potential solutions","volume":"143","author":"Wong","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2022.215661_bib11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.215661_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL death receptor-based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2022.215661_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00262-012-1370-x","article-title":"TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis","volume":"62","author":"Diao","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2022.215661_bib14","doi-asserted-by":"crossref","first-page":"47287","DOI":"10.18632\/oncotarget.10075","article-title":"A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.215661_bib15","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.7150\/jca.46463","article-title":"A tropism-transformed oncolytic adenovirus with dual capsid modifications for enhanced glioblastoma therapy","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2022.215661_bib16","article-title":"Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2022.215661_bib17","article-title":"CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies","author":"Bullock","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2022.215661_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2022.215661_bib19","doi-asserted-by":"crossref","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2022.215661_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01572-7","article-title":"Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain","volume":"8","author":"Singh","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215661_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrrheum.2017.22","article-title":"Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases","volume":"13","author":"Croft","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.canlet.2022.215661_bib22","article-title":"A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route","volume":"7","author":"Zhen Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.215661_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/viro.2002.1406","article-title":"Evaluation of accuracy and precision of adenovirus absorptivity at 260 nm under conditions of complete DNA disruption","volume":"295","author":"Sweeney","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2022.215661_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2022.215661_bib25","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2006-04-017749","article-title":"CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53","volume":"108","author":"Dicker","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2022.215661_bib26","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.215661_bib27","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2022.215661_bib28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.canlet.2022.215661_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01786","article-title":"The oncolytic virus in cancer diagnosis and treatment","volume":"10","author":"Cao","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2022.215661_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2022.215661_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1022302","article-title":"Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy","volume":"4","author":"Qiao","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2022.215661_bib32","article-title":"Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model","author":"Zhang","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2022.215661_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/gt.2010.5","article-title":"TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer","volume":"17","author":"Ziauddin","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2022.215661_bib34","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1002\/jmv.26419","article-title":"The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model","volume":"93","author":"He","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.canlet.2022.215661_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.molcel.2017.01.021","article-title":"The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2","volume":"65","author":"Hartwig","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2022.215661_bib36","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1172\/JCI74056","article-title":"ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis","volume":"124","author":"Condamine","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.215661_bib37","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2003-10-3684","article-title":"Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells","volume":"105","author":"Dicker","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2022.215661_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-017-1182-z","article-title":"Adenovirus-mediated CD40L gene transfer increases Teffector\/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients","volume":"15","author":"Schiza","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2022.215661_bib39","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/neuonc\/noaa126","article-title":"Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors","volume":"22","author":"Wongthida","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2022.215661_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215661_bib41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215661_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215661_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12998-6","article-title":"Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies","volume":"10","author":"Medina-Echeverz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215661_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/eji.201646504","article-title":"CD40L is transferred to antigen-presenting B cells during delivery of T-cell help","volume":"47","author":"Gardell","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2022.215661_bib45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","article-title":"Immunology of adenoviral vectors in cancer therapy","volume":"15","author":"Shaw","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.canlet.2022.215661_bib46","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/mt.2012.116","article-title":"Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo","volume":"20","author":"Young","year":"2012","journal-title":"Mol. Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522001446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522001446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:03:50Z","timestamp":1759593830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522001446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":46,"alternative-id":["S0304383522001446"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215661","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"215661"}}